ST 905
Alternative Names: ST-905Latest Information Update: 06 Jan 2026
At a glance
- Originator Syremis Therapeutics
- Class Antipsychotics
- Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Schizophrenia